Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Hisamitsu Licenses for Percutaneous Pain Killer from Mundipharma
August 27, 2007
-
ARCHIVE R&D NEWS IN BRIEF
August 27, 2007
-
ARCHIVE Toho Pharm., Ohki, and Kokubu to Tie Up
August 27, 2007
-
ARCHIVE OPINION/Our Attitude Leads to Our Altitude
August 27, 2007
-
ARCHIVE Korosho Presents "Emergency Proposals" to Improve Business Practices
August 27, 2007
-
ARCHIVE Industry, Gov't, Academia to Jointly Develop New Medical Devices
August 27, 2007
-
ARCHIVE Discussion on Copyright on Literature Resumed
August 27, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
August 27, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
August 27, 2007
-
ARCHIVE MOF Demands \220 Bil. Cut in Social Security Spending Again in FY2008
August 27, 2007
-
ARCHIVE Chuikyo to Show Road Map for Revisions of Medical Fees in April 2008
August 27, 2007
-
ARCHIVE SEMINAR
August 27, 2007
-
ARCHIVE Korosho Starts Studies for Mutual Acceptance of Clinical Data from Japan, Korea, China
August 27, 2007
-
ARCHIVE DSP to Independently Market Lurasidone in US
August 27, 2007
-
ARCHIVE Indonesia Again Suspends Supply of Influenza Virus Samples: WHO
August 27, 2007
-
ARCHIVE GSK and Takeda to Provide "Boxed" Warning on Avandia and Actos
August 27, 2007
-
ARCHIVE UK High Court Orders NICE to Amend Guidance for Alzheimer's Disease
August 27, 2007
-
ARCHIVE Novartis Concerned about Indian Patent Law - Patent Application for Glivec Rejected
August 27, 2007
-
ARCHIVE Takeda Files MAA for Idebenone in EU
August 27, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
August 27, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…